Edgar Filing: ARATANA THERAPEUTICS, INC. - Form 4

ARATANA THERAPEUTICS, INC. Form 4 October 22, 2013					
FORM A			OMB A	PPROVAL	
UNITED STATES	SECURITIES AND EXCHANGE Washington, D.C. 20549	COMMISSION	OMB Number:	3235-0287	
Subject to Section 16. Form 4 or Form 5 obligations may continue Section 17(a) of the	F CHANGES IN BENEFICIAL OW SECURITIES Section 16(a) of the Securities Exchan Public Utility Holding Company Act of of the Investment Company Act of 19	ge Act of 1934, of 1935 or Section	Expires: Estimated a burden hou response	irs per	
(Print or Type Responses)					
1. Name and Address of Reporting Person <u>*</u> YARNO WENDY L	2. Issuer Name and Ticker or Trading Symbol ARATANA THERAPEUTICS, INC [PETX]	Issuer	p of Reporting Person(s) to Theck all applicable)		
(Last) (First) (Middle) C/O ARATANA THERAPEUTICS, INC., 1901 OLATHE BOULEVARD	3. Date of Earliest Transaction (Month/Day/Year) 10/18/2013	X Director Officer (give below)	title 10%	6 Owner er (specify	
(Street)	4. If Amendment, Date Original Filed(Month/Day/Year)	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting			
KANSAS CITY, KS 66103		Person		porting	
(City) (State) (Zip)	Table I - Non-Derivative Securities Ac	quired, Disposed of	, or Beneficial	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deem Execution any (Month/D	Date, if TransactionAcquired (A) or Code Disposed of (D) ay/Year) (Instr. 8) (Instr. 3, 4 and 5) (A)	Securities F Beneficially (I Owned (I	orm: Direct D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate line for each c		indirectly.			

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of prDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration D (Month/Day/	ate	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (I	D) Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 28.04	10/18/2013		А	13,237	<u>(1)</u>	10/18/2023	Common Stock	13,237

Edgar Filing: ARATANA THERAPEUTICS, INC. - Form 4

Reporting Owners

Reporting Owner Name / Address		Relationships				
		Director	10% Owner	Officer	Other	
YARNO WENDY L C/O ARATANA THERAPEUTICS, INC. 1901 OLATHE BOULEVARD KANSAS CITY, KS 66103		Х				
Signatures						
/s/ Wendy L. Yarno	10/21/2013					
<u>**</u> Signature of Reporting Person	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Vests in four equal installments on each of the first four anniversaries of the grant date, subject to continued service to the Issuer through the applicable vesting dates.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.